Boston biotech joins COVID-19 antibody treatment effort
by Press Release from Outbreak News Today on (#59BKT)
Abpro Corporation announced it has completed dosing all subjects in a Phase 1 clinical trial evaluating the safety of ABP 300, a human neutralizing antibody for the treatment of COVID-19 derived from patients who have recovered from the SARS-CoV2 infection.ABP 300 was developed to confer design features that potentially allow for more potent viral neutralization [...]
The post Boston biotech joins COVID-19 antibody treatment effort appeared first on Outbreak News Today.